Friday 6 November 2026 Export MMED’s income statement to Excel — free account

MiniMed Group, Inc.

MMED Healthcare Medical Instruments & Supplies

MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.

17.07 1.09 −6.00%

Follow MMED

Alert me

Market cap: $5.1B
P/E: 0.0×
Fwd P/E: 27.8×
Dividend yield: —
F-score: n/a
Altman Z: 2.53
Beneish M: −3.09
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.43%

Capital & Financial Ratios $m

Size

Market Cap 5,110.00

Revenue ttm 3,043.00

Net income ttm (320.00)

Free cash flow ttm (452.00)

Net debt Q (207.00)

Valuation

P/E 0.00

Forward P/E 27.80

Price / sales 1.68

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.42

Financial health

Current ratio Q 1.81

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q —

Operating income growth Q —

EPS, this year +154.22%

EPS, next year A +2.00%

Revenue, next year A +10.77%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	—	11	298	207
Receivables	—	570	200	180
Inventory	—	311	341	356
Other	—	48	509	674
	—	939	1,348	1,417

	2024	2025	2026	Q'26
Payables	—	205	163	251
ST’ Debt	—	—	—	—
Other	—	—	137	178
	—	710	702	782

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	—
Earnings	—	—	—
Book Value	—	—	—

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate 0.09 Actual 0.00

−0.80 −0.55 −0.30 −0.04 0.21

Q4 FY26 Miss −0.47

Q1 FY27 Miss −0.09

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY26	−0.21	−0.68	Miss by 0.47
Q1 FY27	0.09	0.00	Miss by 0.09

EPS $

	Jan	Apr	Jul	Oct	Year
’26	—	—	0.00	—	—
’26	(0.47)	—	(0.08)	—	(1.29)
’25	(0.04)	—	—	—	(0.84)

Fiscal quarters ending in the months shown.

Revenue $m

	Jan	Apr	Jul	Oct	Year
’26	—	—	843	—	—
’26	790	—	723	—	3,102
’25	687	—	—	—	2,715

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jan	Apr	Jul	Oct	Year
’26	—	—	(49)	—	—
’26	(27)	—	(141)	—	(197)
’25	57	83	—	—	140

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jan	Apr	Jul	Oct	Year
’26	—	—	(90)	—	—
’26	(194)	—	(194)	—	(420)
’25	(79)	26	—	—	(53)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	TTM Jul ’26	Trend	10 yrs	2027e	2028e	2029e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	2,469	2,715	3,102	3,043		+12.1%	3,436	3,728	4,101	+9.8%
	Gross margin, %	—	—	—	—	—	—	—	58.20	56.28	54.16	53.60		(4.0) pt	Powerpack MiniMed Group, Inc.’s next three years, line by line Analysts expect revenue to grow 9.8% a year to 2029 — slower than the 12.1% of the last 2 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	—	—	—	—	—	(70)	(147)	(189)	(87)		+64.3%
	EBT margin, %	—	—	—	—	—	—	—	(2.84)	(5.41)	(6.09)	(2.86)		(3.2) pt
	Net income	—	—	—	—	—	—	—	(107)	(198)	(317)	(320)		+72.1%
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	—	9.77	10.74	12.09	10.83		+11.3%
	Earnings	—	—	—	—	—	—	—	(0.42)	(0.84)	(1.29)	(0.59)		+74.6%
	Cash flow	—	—	—	—	—	—	—	0.16	0.55	(0.77)	(0.48)		n/m
	Capex	—	—	—	—	—	—	—	(0.59)	(0.76)	(0.87)	(1.13)		+21.8%
	Free cash flow	—	—	—	—	—	—	—	(0.42)	(0.21)	(1.64)	(1.61)		+96.6%
	Book value	—	—	—	—	—	—	—	0.00	13.17	14.07	12.88		n/m
	Shares, m	—	—	—	—	—	—	—	253	253	257	260		+0.7%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	—	—	—	0.00	0.00	0.00	1.68		0.0
	P/B	—	—	—	—	—	—	—	1.35	1.35	0.86	1.42		1.2
	EV/Sales	—	—	—	—	—	—	—	0.00	0.00	0.00	1.62		0.0
	EV/FCF	—	—	—	—	—	—	—	(10.58)	(10.58)	(6.40)	(10.88)		(9.2)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	—	41	140	(197)	(134)		n/m
	Capex	—	—	—	—	—	—	—	(148)	(193)	(223)	(318)		+22.8%
	Free cash flow	—	—	—	—	—	—	—	(107)	(53)	(420)	(452)		+98.1%
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	—	—	229	646	635		+182.1%
	Net debt	—	—	—	—	—	—	—	—	(11)	(298)	(207)		+2,609.1%
	Shareholders’ equity	—	—	—	—	—	—	—	—	3,330	3,611	3,620		+8.4%
Returns, %
Returns, %	ROA	—	—	—	—	—	—	—	0.00	(10.14)	(7.54)	(6.27)		(7.5) pt
	ROIC	—	—	—	—	—	—	—	0.00	(2.73)	(3.58)	(1.61)		(3.6) pt
	ROE	—	—	—	—	—	—	—	0.00	0.00	(9.59)	0.00		(9.6) pt
People
People	Employees	—	—	—	—	—	—	—	—	3,000	2,800	—		(6.7%)
	Revenue/emp, $m	—	—	—	—	—	—	—	0.00	0.91	1.11	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BLCO Bausch + Lomb Corporation	$7.1B	— (loss-making)	749×	+7.34% (above 0%: growing)	n/m	+182.54% (above 0%: growing)	64.65%	11.27%	Compare
TFX Teleflex Incorporated	$6.5B	— (loss-making)	37.4×	+28.88% (above 0%: growing)	−17.33% (below 0%: shrinking)	+220.14% (above 0%: growing)	58.16%	12.77%	Compare
MMSI Merit Medical Systems, Inc.	$5.4B	33.2×	30.7×	+8.35% (above 0%: growing)	+50.53% (above 0%: growing)	+50.18% (above 0%: growing)	48.20%	14.12%	Compare
MMED MiniMed Group, Inc.	$5.1B	— (loss-making)	27.8×	—	n/m	−13.92% (below 0%: shrinking)	55.16%	0.47%
ICUI ICU Medical, Inc.	$4.2B	69.3×	48.8×	+4.37% (above 0%: growing)	n/m	+292.20% (above 0%: growing)	41.89%	9.34%	Compare
NVST Envista Holdings Corporation	$4.0B	6.4×	21.5×	+3.22% (above 0%: growing)	n/m	−6.48% (below 0%: shrinking)	57.93%	74.50%	Compare
PLSE Pulse Biosciences, Inc	$3.9B	— (loss-making)	— (loss-making)	+359.30% (above 0%: growing)	n/m	−1,180.54% (below 0%: shrinking)	51.65%	(6,149.87%)	Compare
STVN Stevanato Group S.p.A.	$3.6B	22.4×	30.2×	+5.91% (above 0%: growing)	+17.53% (above 0%: growing)	+4,089.92% (above 0%: growing)	29.12%	18.51%	Compare
ATRC AtriCure, Inc.	$3.1B	199×	573×	+15.03% (above 0%: growing)	n/m	−0.73% (below 0%: shrinking)	77.27%	2.82%	Compare
Median of peers	$4.1B	33.2×	37.4×	+7.85%	+17.53%	+116.36%	54.79%	12.02%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 21 August 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2026	8.43m	4.38m	71.39

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement